Lenvatinib
Lenvima (lenvatinib) is a prescription brand-name medication classified as a tyrosine kinase inhibitor. It is used to treat certain types of cancer including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. The medication works by targeting and blocking specific proteins that promote cancer cell growth and blood vessel formation.
Lenvima is a targeted cancer therapy used to treat several types of cancer by inhibiting proteins involved in tumor growth and blood vessel formation.
Key facts at a glance
- RxNorm
- 1792372
- Generic
- Lenvima
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Lenvima is FDA-approved for the treatment of adults with differentiated thyroid cancer (DTC) that has progressed despite radioactive iodine therapy, advanced renal cell carcinoma (kidney cancer) in combination with everolimus, unresectable hepatocellular carcinoma (liver cancer), and advanced endometrial carcinoma in combination with pembrolizumab.
Lenvima is a tyrosine kinase inhibitor that works by blocking multiple receptor kinases involved in tumor growth and angiogenesis (formation of new blood vessels that feed tumors). Specifically, it inhibits vascular endothelial growth factor (VEGF) receptors and other related kinases, which helps slow tumor progression and can cause tumor shrinkage.
Lenvima may cause serious side effects including hypertension, heart failure, arterial blood clots, liver problems, kidney problems, and gastrointestinal perforation. It can also impair wound healing and may cause fetal harm if used during pregnancy. Patients should be monitored regularly for blood pressure, liver function, and signs of cardiac or renal toxicity. Complete prescribing information should be reviewed for all warnings and contraindications.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy